Coagulation Factor VIIa (Recombinant)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Coagulation Factor VIIa (Recombinant), covering 2025-07-09 to 2025-07-09. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM [Phase 3]